Intermediate-dose HAD Regimen for CEBPA Double-mutated AML
Clinical trial NCT06529250 · RECRUITING
Trial details
- NCT number
- NCT06529250
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- RECRUITING
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-13
- Primary completion
- 2027-08-30
- Enrollment
- 148
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.